|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.03 USD | +0.91% |
|
-0.85% | +79.35% |
| 10/07 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 15/05 | ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 9.89Cr | - | - | - | - | - |
| 1,05700Cr | |||||
| 62TCr | |||||
| 45TCr | |||||
| 34TCr | |||||
| 30TCr |
- Stock Market
- Stocks
- ICCC Stock
- Charts ImmuCell Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
